Optimizing the Care of Patients with Moderate-to-Severe Asthma: Minimizing Asthma Exacerbations with Biologic Therapy
February 25, 2022
Symposium:
10:30 PM – 11:30 PM Eastern
9:30 PM – 10:30 PM Central
8:30 PM – 9:30 PM Mountain/Arizona
7:30 PM – 8:30 PM Pacific
Program Overview
This live satellite symposium consists of presentations from expert faculty and simulation challenge animations that will explain immune dysfunction and the pathogenesis of moderate-to-severe asthma, currently available and emerging targeted therapies used for asthma, and the usefulness and application of guidelines and biomarkers to guide treatment selection for this disease.
This program is not sponsored or programmed by the AAAAI.
Target Audience
This activity is designed to meet the educational needs of allergists, immunologists, and other health care providers involved in the care of patients with moderate-to-severe asthma.
Learning Objectives
Upon the completion of this program, attendees should be able to:
- Utilize biomarkers to identify asthma phenotypes and endotypes and to personalize the selection of therapy for patients with moderate-to-severe disease
- Differentiate between uncontrolled and severe asthma and identify patients who require step-up therapy to reduce asthma exacerbations and oral corticosteroid use
- Develop evidence-based treatment plans for patients with moderate-to-severe asthma that consider exacerbation risks, comorbidities, and quality of life
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com
This activity is provided by Med Learning Group
This activity is co-provided by Ultimate Medical Academy/Complete Conference Management (CCM).
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi Genzyme.
Release date: February 25, 2022
Expiration date: February 25, 2022
Estimated time to completion: 1.0 hours
